Clinical Trial Update: Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of recombinant activated Factor VII in severely injured trauma patients has completed. The trial was sponsored …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Coagulopathy
• Trauma

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Acquired Bleeding Disorder, Trauma | Phase 2 | Status: COMPLETED